Biogen Idec (NQ:BIIB)

Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗

Performance

52-Week Range

235.36

138.0052W Low 230.4952W High

1 Week

215.731W Low 228.001W High

Biogen Idec (BIIB) traded between $138.00 and $230.49 over the past 52 weeks and last traded at $235.36. Over the past week it ranged between $215.73 and $228.00.

Past 12 Months

+5.3%

+8.4%

+12.6%

+33.5%

+32.4%

+62.7%

1W +$11.77

1M +$18.21

3M +$26.33

6M +$59.00

YTD +$57.54

1Y +$90.67

BIIB was +62.7% over the past year, +33.5% over six months, +32.4% year to date, +5.3% in the last week.

12 Months vs Market

BIIB

+62.7%

DIA

+12.4%

SPY

+17.3%

QQQ

+23.9%

IWM

+13.8%

Over the past 12 months BIIB returned +62.7% versus DIA (Dow) +12.4%, SPY (S&P 500) +17.3%, QQQ (Nasdaq 100) +23.9% and IWM (Russell 2000) +13.8%.

Volume & Liquidity 0.70× 3-mo avg

Today 739,403 3-mo avg 1.1M

1.1M

YTD

1.2M

1.4M

BIIB most recently traded 739,403 shares against a 3-month average daily volume of 1.1M.

More News

Today 8:35 EDT

Via Chartmill

2 Surging Stocks for Long-Term Investors and 1 We Brush Off

Today 0:41 EDT

Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)

October 07, 2026

Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus

October 02, 2026

From Biogen Inc.

1 Profitable Stock Worth Investigating and 2 We Ignore

October 01, 2026

Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks

September 30, 2026

Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack

September 24, 2026

Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks

September 23, 2026

Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)

September 21, 2026

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

September 17, 2026

From Biogen Inc.

Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience ↗

September 15, 2026

Via MarketBeat

Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology ↗

September 12, 2026

Via MarketBeat

Thursday's session: top gainers and losers in the S&P500 index ↗

September 10, 2026

Via Chartmill

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks

September 09, 2026

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

September 08, 2026

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

From BioMedWire

Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)

September 07, 2026

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

September 03, 2026

From Biogen Inc.